Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1099-1104

  Komachi, Mayumi ^a   Sato, Koichi ^a   Tobo, Masayuki ^a   Mogi, Chihiro ^a   Yamada, Takayuki ^a   Ohta, Hideo ^b   Tomura, Hideaki ^a   Kimura, Takao ^a   Im, Dong Soon ^c   Yanagida, Keisuke ^d   Ishii, Satoshi ^e   Takeyoshi, Izumi ^f   Okajima, Fumikazu ^a  

^a GUNMA UNIVERSITY   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c Pusan National University   (South Korea)

^d UNIVERSITY OF TOKYO   (Japan)

^e AKITA UNIVERSITY   (Japan)

^f GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLOCKING AGENT; KI 16198; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; IN VIVO STUDY; INOCULATION; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ASCITES; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; ISOXAZOLES; LYSOPHOSPHOLIPIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PROPIONATES; RECEPTORS, LYSOPHOSPHATIDIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862815796     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02246.x     Document Type: Article

References (31)

1. Oberstein PE, Saif MW. First-line treatment for advanced pancreatic cancer. JOP J Pancreas 2011; 12: 96-100.
2. Maheshwari V, Moser AJ. Current management of locally advanced pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 356-64.
3. Xiao YJ, Schwartz B, Washington M et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 2001; 290: 302-13.
4. Yamada T, Sato K, Komachi M et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 2004; 279: 6595-605.
5. Komachi M, Tomura H, Malchinkhuu E et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis 2009; 30: 457-65.
6. Shida D, Kitayama J, Yamaguchi H et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 2003; 63: 1706-11.
7. Hama K, Aoki J, Fukaya M et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 2004; 279: 17.
8. Chen M, Towers LN, O'Connor KL. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am J Physiol Cell Physiol 2007; 292: C1927-33.
9. Yu S, Murph MM, Lu Y et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100: 1630-42.
10. Ren J, Xiao YJ, Singh LS et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006; 66: 3006-14.
11. Ohta H, Sato K, Murata N et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003; 64: 994-1005.
12. Malchinkhuu E, Sato K, Horiuchi Y et al. Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells. Oncogene 2005; 24: 6676-88.
13. Shida D, Fang X, Kordula T et al. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 2008; 68: 6569-77.
14. Yamada T, Okajima F, Adachi M, Ohwada S, Kondo Y. Growth dependency of a new human pancreatic cancer cell line, YAPC, on autocrine interleukin-1alpha stimulation. Int J Cancer 1998; 76: 141-7.
15. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003; 278: 25600-6.
16. Yanagida K, Masago K, Nakanishi H et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 2009; 284: 17.
17. Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA, Billiard J. LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem 2010; 109: 794-800.
18. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006; 281: 23.
19. Tian M, Cui YZ, Song GH et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008; 8: 241.
20. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-97.
21. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
22. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-91.
23. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 2006; 103: 9643-8.
24. Baker DL, Fujiwara Y, Pigg KR et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 2006; 281: 22.
25. Zhang H, Xu X, Gajewiak J et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 2009; 69: 5441-9.
26. Xu X, Prestwich GD. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010; 116: 1739-50.
27. Furui T, LaPushin R, Mao M et al. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 1999; 5: 4308-18.
28. Yokoyama M, Ochi K, Ichimura M et al. Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 2002; 24: 344-7.
29. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481-90.
30. Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta 2010; 1803: 103-20.
31. He Y, Liu XD, Chen ZY et al. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res 2007; 13: 3115-24.